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The formation of neurofibrillary tangles (NFTs), oxidative stress and neuroinflammation have emerged 
as key targets for the treatment of Alzheimer’s disease (AD), the most prevalent neurodegenerative 
disorder. These pathological hallmarks are closely related to the over-activity of the enzyme GSK3β 
and the downregulation of the defense pathway Nrf2-EpRE observed in AD patients. Herein, we report 
the synthesis and pharmacological evaluation of a new family of multitarget 2,4-dihydropyrano[2,3-c]
pyrazoles as dual GSK3β inhibitors and Nrf2 inducers. These compounds are able to inhibit GSK3β and 
induce the Nrf2 phase II antioxidant and anti-inflammatory pathway at micromolar concentrations, 
showing interesting structure-activity relationships. The association of both activities has resulted in 
a remarkable anti-inflammatory ability with an interesting neuroprotective profile on in vitro models 
of neuronal death induced by oxidative stress and energy depletion and AD. Furthermore, none of the 
compounds exhibited in vitro neurotoxicity or hepatotoxicity and hence they had improved safety 
profiles compared to the known electrophilic Nrf2 inducers. In conclusion, the combination of both 
activities in this family of multitarget compounds confers them a notable interest for the development 
of lead compounds for the treatment of AD.
Alzheimer’s disease (AD) is the most common neurodegenerative disease1, with a prevalence of more than 50 
million cases worldwide in 2015, a number that is expected to reach 135 million in 2050. After more than a cen-
tury of intensive research, the causes of AD are still largely unknown and consequently, the discovery of effective 
therapies remains a critical objective of modern medicine2. AD is characterized by the formation of intracellu-
lar neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau protein, and extracellular amyloid-β 
plaques (Aβ ), formed by amyloid-β peptide. Both hallmarks, along with extensive oxidative stress and chronic 
neuroinflammation, are considered major effectors of the complex AD neurodegenerative progression.
Several studies have demonstrated a direct correlation between the appearance of NFTs and the cognitive 
decline observed in AD3 suggesting that the tau component is a primary target in drug development programs 
in AD4. Glycogen synthase kinase-3β (GSK3β ) is one of the most important kinases implicated in tau hyper-
phosphorylation, and it plays a pivotal role in the etiopathogenesis of AD5–7. GSK3β is over-expressed in the 
brain of AD patients, directly contributing to the formation of NFTs8. Furthermore, this kinase is also related 
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to Aβ deposition9, oxidative stress and gliosis5. Recently, it has also been shown that GSK3β is a key mediator of 
apoptosis, thereby taking part in the mechanism involved in the neuronal loss in AD10. Thus, the search of GSK3β 
inhibitors has been extensively pursued and several compounds have reached clinical trials. However, the results 
have been disappointing either by lack of therapeutic action or side effects11 due to the wide range of physiological 
actions in which GSK3β is known to be involved12.
Oxidative stress is an important phenomenon clearly involved in the pathogenesis and progression of AD13,14. 
Oxidative stress is not only a consequence of the primary AD cascade of events, but also a cause of the initial onset 
of the disease15. It is present in the preliminary phase, known as mild cognitive impairment, when the Aβ plaques 
and the NFTs are not yet evident16. Furthermore, there are convergent neurotoxic effects of hyperphosphorylated 
tau, Aβ aggregates and oxidative stress whereas they induce and increase their reciprocal appearance in a positive 
feedback loop, intensifying neuronal damage and accelerating cognitive decline17,18. To counteract the harm-
ful effects generated by oxidative stress, cells employ the nuclear factor erythroid 2-related factor 2/electrophile 
response element (Nrf2/EpRE) transcriptional pathway which promotes the synthesis of numerous antioxidant 
and anti-inflammatory enzymes19. Despite extensive evidence of high levels of oxidative stress in AD brains, 
Nrf2 is predominantly cytoplasmic in neurons, demonstrating the failure of this pathway20. Thus, the Nrf2-EpRE 
pathway has emerged as a promising pharmacological target for the treatment of AD21–26. Furthermore, there is 
evidence that the activities of GSK3β and Nrf2 are negatively correlated, thus increasing neuronal sensitivity to 
oxidative stress in AD27,28. Indeed, GSK3β is involved in the down-regulation of Nrf2 and control of its subcellular 
distribution29–31. In fact, several reports have demonstrated the interest in targeting GSK3β and Nrf2 as therapeu-
tic strategies in AD32,33.
It is well established that both extensive oxidative stress and protein aggregates induce glial activation leading 
to chronic neuroinflammation34. Once activated, microglia produce pro-inflammatory cytokines, chemokines 
and free radical species, increasing oxidative stress, and thereby accelerating the neurodegenerative process. The 
chronic inflammatory status is also increased by the over-activity of GSK3β through several pathways11. It has also 
been demonstrated that neuroinflammation precedes and is sufficient to cause AD-like pathology35, implicating 
immune reactions early in the pathogenic process.
In this context, we were interested in finding a multitargeted drug combining two main activities: (1) GSK3β 
inhibition to diminish tau phosphorylation and to decrease cell death, improving neuronal survival and (2) Nrf2 
induction properties, directed to reduce oxidative stress and the neuroinflammatory status. Furthermore, Nrf2 
induction has proven to decrease the levels of phosphorylated tau protein by increasing the autophagy adaptor 
protein NDP5236. Therefore, the inclusion of both activities, GSK3β inhibition and Nrf2 induction, in a single 
molecule would reduce tau hyperphosphorylation by inhibiting the kinase and, at the same time, would help the 
cell to eliminate the aberrant hyperphosphorylated tau by facilitating its clearance. In this study, we present the 
synthesis, as well as the enzymatic and biological evaluation of the first class of compounds with dual activity as 
GSK3β inhibitors and Nrf2 inducers, providing a new therapeutic strategy against AD.
Results and Discussion
Based on the chemical structure of the GSK3β inhibitors 137 and 238 (Fig. 1), we thought that compounds bearing 
the 1,4-dihydropyridine core or the isostere 4H-pyran could be suitable as GSK3β inhibitors and we searched 
for their potential Nrf2 induction. We selected several compounds from our “in house” chemical library39–42 and 
screened them as potential GSK3β inhibitors and Nrf2 inducers. Successfully, we found that compounds bearing 
the 6-amino-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (Fig. 1) were able to inhibit GSK3β and to induce 
Nrf2 at micromolar concentrations. These preliminary results prompted us to synthetize a small chemical library 
using this structural core in order to establish potential structure-activity relationships for future hit-to-lead 
optimization.
Chemistry. The synthesis of a 2,4-dihydropyrano[2,3-c]pyrazole library was achieved via a variation of a 
known three-component reaction43,44 between 5-methyl-1H-pyrazol-3(2H)-one 3 (previously synthesized by 
condensation of hydrazine and ethyl acetoacetate), aromatic aldehydes 4a–t and malononitrile, in refluxing eth-
anol, employing ammonium acetate as promoter of the reaction (Fig. 2).
This method allowed the preparation in good to excellent yields of the compounds 5, bearing H (5a), 
electron-donating (5b–g) or electron-withdrawing (5h–p) groups at different positions on the aldehyde aromatic 
Figure 1. Selection of 2,4-dihydropyrano[2,3-c]pyrazole compounds based on structural features observed 
in known GSK3β inhibitors (1 and 2). 
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ring. To introduce further structural diversity in the 2,4-dihydropyrano[2,3-c]pyrazole derivatives, we also syn-
thesized compounds bearing heterocyclic moieties at the C-4 position (5q–t).
We synthesized also the corresponding dihydro-2H-pyrazole[3,4-b]pyridine analogue 7 for comparison pur-
poses. The dihydropyridine derivative 7 was obtained using the same three-component protocol from 3-methyl-
1H-pyrazol-5-amine 6, benzaldehyde 4a and malononitrile in refluxing dry ethanol, using dry ammonium 
acetate as a promoter of the reaction (Fig. 2B).
Pharmacology: Dual target study: GSK3β inhibition and Nrf2 induction ability of compounds 
5a–t and 7. Compounds 5a–t were tested as potential GSK3β inhibitors using a luminescence Kinase-Glo 
assay. All compounds were assayed at four concentrations (0.1, 1, 10 and 30 μ M) and IC50 values and their respec-
tive apparent equilibrium dissociation constant (Ki) values are summarized in Table 1. The known GSK3β inhibi-
tor SB216763 was included as a positive control and compound 2 for comparative purposes. Inhibitory potencies 
ranged from 3.77 μ M of compound 5m (p-Br) to 21.4 μ M of compound 5f (m-Me). Regarding the substituents 
on the aromatic ring at the C-4 position, compounds bearing electron-withdrawing substituents were generally 
more potent inhibitors than those with an electron-donating substituent. Taking into account the position of 
the substituent, the inhibitory potency increased in the following way: ortho < meta < para. For example, com-
pounds 5b, 5c and 5d bearing an o-OMe, m-OMe and p-OMe substituents respectively, increased their inhibitory 
potency from 16.4 μ M (ortho-position) to 7.20 μ M (meta-position) and to 6.60 μ M (para-position). Interestingly, 
this behaviour was reversed in the case of the nitro compounds, where the ortho-substituted derivative 5n was 
the most potent (IC50 = 3.89 μ M), followed by the meta (5o, IC50 = 7.20 μ M) and the para-substituted derivatives 
(5p, IC50 = 16.3 μ M). This inversion of the inhibitory tendency might be related to a different interaction pattern 
with the enzyme.
Considering the derivatives with a heterocyclic substituent, some correlations can be drawn. The replacement 
of the oxygen atom in derivative 5q (2-furyl) by sulfur 5r (2-thienyl) reduced the inhibitory potency more than 
two fold, from 14.8 μ M to over 30 μ M and the change of the nitrogen position in the pyridine ring from 3 (5s) to 
4 (5t) improved the inhibitory capability more than 3.6 times.
Figure 2. (A) Scope of the three-component synthesis of pyrano[2,3-c]pyrazoles 5a–t. (B) Three-component 
synthesis of 6-amino-3-methyl-4-phenyl-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine-5-carbonitrile 7.
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Finally, the dihydropyridine derivative 7 showed an IC50 value of 18.6 μ M, demonstrating an improved inhib-
itory activity compared to its phenyl analogue 5a. The enhanced inhibitory activity of 7 is undoubtedly related to 
the inclusion of the NH moiety into the six-member ring.
Thereafter, we tested the ability of the compounds to induce the Nrf2 transcription factor. We used an 
Nrf2-dependent luciferase reporter assay in the AREc32 cell line45. Cells were cultured for 24 h and then treated 
with increasing concentrations of compounds 5a–t (0.3, 3, 10 and 30 μ M), including the known inducer sulfora-
phane, containing an isothiocyanate motive as positive control. As shown in Table 1, almost all compounds were 
able to significantly increase luciferase activity, with CD (concentration required to double the basal luciferase 
reporter activity) values ranging from 2.5 μ M (5t, 4-pyr) to over 30 μ M (ortho-substituted derivatives and 7).
Regarding SAR analysis, in general, compounds bearing electron-withdrawing groups were more potent 
inducers than those with an electron-donating group. Comparing the different positions on the aromatic ring at 
C4, Nrf2 induction properties improved from ortho- to para- and meta-, with meta-derivatives being the most 
potent inducers. In all cases, ortho derivatives were poor Nrf2 inducers with CD values over 30 μ M. Interestingly, 
in this experiment the nitro derivatives exerted a different behavior, demonstrated by the CD value of the o-NO2 
derivative (5n, CD = 11.3 μ M), being slightly more potent than the m-NO2 derivative (5o, CD = 18.9 μ M).
The meta derivatives were, except for the nitro derivative, better inducers; being compound 5j being the most 
potent of the phenyl-substituted derivatives (CD = 5.38 μ M). The electronic effect of the substituent at the para- 
position was very important, as compounds bearing electron-donating substituents, namely 5d (p-OMe) and 5g 
(p-Me), were poor Nrf2 inducers (CD = 25.3 and 25.4 μ M, respectively). On the other hand, electron-withdrawing 
derivatives, 5h (p-F), 5k (p-Cl), 5m (p-Br), 5p (p-NO2), were significantly more potent, showing CD values 
between 1.7 and 3 fold more potent than electron-donating para- substituted derivatives. Finally, looking at the 
heterocycle-substituted derivatives, compound 5t bearing a 4-pyridyl substituent was the most potent inducer 
with a CD value of 2.5 μ M.
Interestingly, the fused dihydropyridine 7 was completely unable to induce Nrf2, even at higher con-
centrations (60 and 100 μ M) (see Supporting Information), although it was a better GSK3β inhibitor than its 
Compound Ar GSK3β IC50 (μM) Ki (μM) CD (μM)a
Sulforaphane — — 0.54 ± 0.07
SB 216763 — 0.034 ± 0.01 0.0091 > 30
2 — 1.538 — —
5a Ph > 30 — 20.5 ± 3.4
5b 2-OCH3Ph 16.4 ± 1.8 11.5 > 30
5c 3-OCH3Ph 7.20 ± 0.7 5.04 11.3 ± 1.3
5d 4-OCH3Ph 6.60 ± 1.7 4.63 25.3 ± 2.4
5e 2-CH3Ph > 30 — > 30
5f 3-CH3Ph 21.4 ± 4.6 15.0 14.1 ± 2.1
5g 4-CH3Ph 17.5 ± 1.9 12.3 25.4 ± 2.5
5h 4-FPh 17.9 ± 1.5 12.5 14.6 ± 4.0
5i 2-ClPh > 30 — 23.5 ± 3.2
5j 3-ClPh 20.5 ± 8.0 14.4 5.38 ± 0.5
5k 4-ClPh 6.29 ± 2.6 4.41 8.31 ± 1.5
5l 2-BrPh > 30 — > 30
5m 4-BrPh 3.77 ± 2.0 2.64 9.37 ± 1.4
5n 2-NO2Ph 3.89 ± 1.9 2.72 11.3 ± 5.5
5o 3-NO2Ph 7.20 ± 1.6 5.04 18.9 ± 2.9
5p 4-NO2Ph 16.3 ± 2.8 11.4 15.0 ± 4.3
5q 2-Furyl 14.8 ± 4.8 10.4 25.2 ± 2.4
5r 2-Thienyl > 30 — 17.6 ± 8.4
5s 3-Pyridyl > 30 — 8.91 ± 2.2
5t 4-Pyridyl 8.28 ± 0.7 5.80 2.48 ± 1.4
7 Ph 18.6 ± 0.4 13.1 > 100
Table 1. GSK3β inhibition (IC50 and Ki values) and Nrf2 induction capability (CD values) for the 
2,4-dihydropyrano[2,3-c]pyrazole derivatives 5a–t and dihydro-2H-pyrazole[3,4-b]pyridine 7. IC50 values 
were calculated from concentration-response curves of GSK3β activity as the concentration of inhibitor 
producing 50% reduction of enzyme activity. All compounds were incubated at four different concentrations 
with the enzyme and specific activity was measured after 1 h. The IC50 value obtained for each compound was 
used to calculate the apparent equilibrium dissociation constant Ki, using the Cheng-Prusoff equation (see 
experimental section)68,69. AREc32 cells were treated with increasing concentrations of the corresponding 
compound for 24 h and thereafter, luciferase reporter activity was measured. Data are expressed as the 
concentration required to double the specific luciferase reporter activity (CD). aData are means ± SEM of four 
different experiments in duplicate.
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dihydropyrano[2,3-c]pyrazole analogue compound 5a. This remarkable result indicates that the Nrf2 induction 
capability of the dihydropyrano[2,3-c]pyrazole derivatives 5a–t is an intrinsic property of the core structure.
Proposed binding pose of 5m into the ATP binding site of GSK3β. In order to obtain a deeper 
insight into the molecular interactions of compounds 5a–t with GSK3β at the atomic level, we performed docking 
calculations. To this end, we selected the most potent GSK3β inhibitor found in this family to study its potential 
binding mode. Docking studies were performed with the AutoDock Vina program using the ATP binding site 
of GSK3β (PDB code 1PYX). We studied both enantiomers of compound 5m, which showed similar poses and 
modes of interaction with a 180° flip position of the dihydropyrano[2,3-c]pyrazole core from R to S enantiomers. 
Thus, the best docking solutions for the dihydropyrano[2,3-c]pyrazole core of the R enantiomer shows a hydro-
gen bond of the N atom of the pyrazole ring to the backbone peptide bond of Asp200 and another H-bond contact 
between the carbonyl group of Asp133 and the amino moiety of the inhibitor (Fig. 3A). Conversely, docking 
solutions of S enantiomer of compound 5m, which is flipped 180°, predict that the NH group of the pyrazole ring 
forms a hydrogen bonding interaction to the backbone carbonyl of Val135 and that the N atom of the same ring 
H-binds to the backbone NH of Val135 (Fig. 3B).
Nrf2 induction properties are independent of the GSK3β inhibitory capability. Under stress con-
ditions, GSK3β is over-activated and down-regulates Nrf227, thus GSK3β inhibition can lead to Nrf2 induction 
as previously demonstrated27,46,47. However, in our experimental conditions GSK3β inhibition did not induce 
luciferase expression in the AREc32 cell line as demonstrated by the inability of the GSK3β inhibitor SB216763 to 
induce Nrf2 transcriptional activity (see Supporting Information). This result might be explained by the existence 
of several autocrine pathways that limit the effect of GSK3β over Nrf2 in this particular cell line48. To further eval-
uate the potential relationship between GSK3β inhibition and the Nrf2 induction properties we used two different 
approaches. Firstly, we used a pharmacological approach to inhibit the enzyme by using lithium, a well-known 
GSK3β inhibitor able to inhibit GSK3β activity with a Ki of 2 μ M49. Incubation with Li (10 mM) inhibits almost 
completely GSK3β activity allowing us to evaluate the Nrf2 induction capability of our derivatives after phar-
macological ablation of GSK3β 49. We selected compound 5m as the most potent GSK3β inhibitor to be assessed 
under these conditions. Cells were treated with compound 5m at increasing concentrations alone or in presence 
of Li (10 mM) during 24 h and thereafter, luciferase activity was evaluated. As shown in Fig. 4A, compound 5m 
was able to increase luciferase activity from 3 μ M to 30 μ M when it was incubated alone or in presence of Li 
(10 mM) to the same extent and without statistically significant differences. Secondly, to corroborate the inde-
pendence of the Nrf2 induction properties of our derivatives from their GSK3β inhibitory properties, we used 
GSK3β knock down experimental conditions using siRNA. Knockdown of GSK3β by 85.7% according to western 
blot analysis (Fig. 4B) did not affect the Nrf2 induction potency of compound 5m. After knockdown of GSK3β , 
AREc32 cells were incubated with compound 5m (10 μ M) during 24 h (Fig. 4B). Subsequently, luciferase activ-
ity and HO-1 expression were analyzed. As shown in Fig. 4C, knockdown of GSK3β moderately increased the 
activity of luciferase. Compound 5m (10 μ M) increased luciferase activity 2.2-fold compared to basal conditions 
in cells previously treated with scramble control siRNA. Similarly, 5m was also able to increase luciferase activity 
2.8-fold compared to basal conditions (Fig. 4C) when GSK3β was silenced. Similar results were obtained when 
HO-1 expression was analyzed (Fig. 4D), compound 5m increased HO-1 expression 3.9 times after scramble 
treatment and 3.5 times after knockdown of GSK3β showing no statistical differences between both conditions. 
These results demonstrate that the Nrf2 induction mechanism of compound 5m is independent of its GSK3β 
inhibitory properties. Thus, both mechanisms of action are complementary and independent.
Recently, inhibitors of the Nrf2-Keap1 protein-protein interaction have been reported as potent 
non-electrophilic Nrf2 inducers50, and thus, we tested such inhibition as a potential mechanism of action. 
Figure 3. Proposed binding mode of 5m into ATP-binding site of GSK3β. Docking studies of the p-bromo 
derivative 5m (R enantiomer, green sticks, panel A; S enantiomer, dark blue sticks, panel B) at the ATP binding 
site of GSK3β .
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Unfortunately, fluorescence polarization and differential scanning fluorimetry assays indicated that compounds 
5a–t are not able to inhibit the Nrf2-Keap1 interaction (see the Supporting Information). Therefore, further 
studies will be undertaken in order to elucidate the exact mechanism of action involved in the Nrf2 induction.
Compounds 5a–t exert neuroprotection against Tau hyperphosphorylation and rotenone/oli-
gomycin induced cytotoxicity. As described above, tau hyperphosphorylation and the presence of neu-
rofibrillary tangles is one of the central hallmarks in AD, and the main kinase related to tau hyperphosphorylation 
in AD is GSK3β . We selected a specific in vitro model of AD to test the potential neuroprotective activity of 
these derivatives against tau hyperphosphorylation. Okadaic acid (OA) exerts its toxicity by selectively inhibiting 
protein phosphatases 1 and 2A51, inducing tau-hyperphosphorylation and aggregation52. Furthermore, it also 
increases oxidative stress leading to cell death53,54. Results are expressed as percentage of protection, meaning the 
increase in cells survival compared to the toxicity induced by OA. In all experiments, the neuroprotective agent 
melatonin, and the GSK3β inhibitor SB216763 were included for comparative purposes (Fig. 5A).
In general, all tested compounds showed neuroprotective activities at 1 μ M concentration, with protection 
percentages ranging from 27.7% for compound 5a (Ph) to 56.2% for compound 5c (m-OMe). Among them, 
compounds 5c (m-OMe), 5f (m-Me), 5m (p-Br) and 5t (4-pyridyl) showed neuroprotective activities over 50%. 
Compared to reference compounds, most derivatives were able to protect neuroblastoma cells better than mel-
atonin and SB216763, although they are less potent GSK3β inhibitors than the latter, proving that their neuro-
protective effect also depends on Nrf2 induction. This observation is in agreement with the fact that OA induced 
toxicity depends on tau hyperphosphorylation and oxidative stress. From SAR studies, the inclusion of substit-
uents at the aromatic ring improved their protective activity in all cases, using as a reference phenyl derivative 
5a, which showed the poorest neuroprotective effect as well as poor GSK3β inhibition (> 30 μ M) and poor Nrf2 
induction properties (CD = 20.5 μ M). The general behavior was the enhancement of the protective capabilities 
when the GSK3β inhibitory potency and the Nrf2 induction potency increased. This is particularly evident in the 
case of compounds 5c (m-OMe), 5m (p-Br) and 5t (4-pyridyl), which showed protection percentages over 50%, 
are among the most potent GSK3β inhibitors (IC50 lower than 10 μ M) and Nrf2 inducers (CD lower than 10 μ M 
for 5m and 5t). Similarly, derivative 5c showed a similar potency to compound 5d as a GSK3β inhibitor, but 5c 
was 2.2 times better as an Nrf2 inducer, and showed the highest neuroprotective activity (56.2%) against OA.
Figure 4. Nrf2 induction properties are independent of the GSK3β inhibitory activity. (A) Luciferase 
activity induced by compound 5m alone and in presence of lithium compared to basal conditions. (B) GSK3β 
silencing efficiency achieved by treating AREc32 cells with 25 nM of siRNA and 2 μ L of DharmaFECT1 during 
48 h. (C) Luciferase activity induced by compound 5m (10 μ M) in AREc32 cells after 24 h. Cells were previously 
treated with scramble (white) or siGSK3β (black) silencing RNAs during 48 h. (D) HO-1 expression induced by 
compound 5m (10 μ M) measured at the same experimental conditions used previously. Values are expressed as 
mean ± SEM of three independent experiments in duplicate. ###p < 0.001; ##p < 0.01; #p < 0.05 compared to the 
correspondent basal conditions.
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However, this trend was different in the case of the nitro derivatives, as also observed for the inhibition of 
GSK3β and Nrf2 induction. In this case, compound 5n (o-NO2) had the highest inhibitory potency (IC50 = 3.9 μ M) 
among nitro derivatives and good Nrf2 induction properties, showed a lower neuroprotective effect (34.7%) than 
its m-NO2 substituted analogue 5o (48% protection), that was a two-fold poorer GSK3β inhibitor and also a less 
potent Nrf2 inducer.
As stated in the Introduction, oxidative stress is considered one of the main causes of neuronal death in AD. 
Therefore, we were interested in evaluating the potential antioxidant activity of compounds 5a–t in a model of 
oxidative stress and energy depletion, which in turn increase cell death. For this purpose, we selected the com-
bination of rotenone (30 μ M) and oligomycin A (10 μ M) (R/O) to induce neurotoxicity as a model system23,40 to 
evaluate the potential neuroprotective activity of the compounds. Melatonin, a well-known antioxidant natural 
compound, was included as a positive control.
As shown in Fig. 5B, compounds 5a–t exhibited interesting neuroprotective properties against the cytotoxicity 
induced by the combination of R/O, with neuroprotection values ranging from 24.1% of compound 5l (o-Br) to 
57.9% of compound 5s (3-pyridyl). Importantly, almost all derivatives showed a greater neuroprotective effect 
than melatonin. In general, the antioxidant neuroprotective effect was proportional to the Nrf2 induction capa-
bility that, in turn, depends on the type of substituent and its position on the aromatic ring.
As described for Nrf2 induction, the antioxidant neuroprotective activity increased from ortho- to para- 
and meta- derivatives, following the same trend as the Nrf2 induction properties. For example, compounds 5b 
(o-OMe) and 5d (p-OMe), were poor Nrf2 inducers and both showed similar neuroprotective effects (39.1% and 
Figure 5. Compounds 5a–t exert neuroprotection in in vitro models of AD. Neuroprotective effect 
of compounds 5a–t at 1 μ M, melatonin (1 μ M) and SB216763 (1 μ M) against toxicity elicited by tau 
hyperphosphorylation (A, OA, 20 nM) or oxidative stress and energy depletion (B, R/O, 30/10 μ M). SH-SY5Y 
cells were pre-incubated for 24 h with compounds 5a–t, melatonin or SB216763 at 1 μ M. Then, treatments 
were removed and cells were co-incubated with each treatment and okadaic acid for 18 h or R/O for 24 h. Cell 
viability was measured by the MTT reduction assay. Values are expressed as mean ± SEM of five independent 
experiments in triplicate. ***p < 0.001; **p < 0.01 respect to toxic stimuli treated cells, considered as 0% of 
protection.
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38.8%, respectively). Instead, compound 5c, bearing a meta-methoxy substitution showed the best Nrf2-inducer 
capability among methoxy derivatives, and showed an improved neuroprotective effect (55.3%), being the second 
best neuroprotectant agent of the family. This tendency was reproduced for methyl, chloro and nitro substituted 
derivatives. Finally, the 3-pyridyl analogue, the second most potent Nrf2 inducer, was the best neuroprotectant 
agent against the R/O combination, being able to reduce 57.9% of cell death.
Compounds 5a–t reduced nitrite and ROS production in primary glial cultures stimulated with 
lipopolysaccharide. The overexpression and/or increased activity of GSK3β have been widely associated 
with increased microglial activation in AD, leading to cell death55. On the other hand, the deregulation of the 
Nrf2-EpRE pathway in AD20 leads to a situation of exacerbated oxidative stress that also induces glial activation. 
Finally, activated glial cells liberate different pro-inflammatory cytokines (TNFα and IL1β , among others) and 
induce the activation of NADPH oxidase (NOX) and the over-expression of the inducible nitric oxide synthase 
(iNOS), increasing the levels of oxidative stress and enhancing oxidative damage. The cross-link between GSK3β , 
Nrf2 and the production of free radicals generates a positive auto-regulated loop, leading to a situation of chronic 
inflammation that has been widely described as a pathological hallmark of AD.
Therefore, we envisaged the study of compounds 5a–t as potential anti-inflammatory agents. We used primary 
rat glial cells treated with lipopolysaccharide (LPS) to induce the production of nitrites and ROS as a model of 
glial activation. Nitrite production is directly proportional to the expression of the iNOS, that is over-expressed 
when LPS activates glial cells. ROS production is proportional to NOX activation after stimulation with LPS. 
Results are summarized in Table 2 as IC50s of nitrite production reduction and ROS production reduction. We 
have included sulforaphane as control in all experiments (see the Supporting Information).
In terms of substituent position, the capacity to reduce nitrite release improved from ortho to para and meta, 
following a similar tendency to Nrf2 induction (Table 1). In general, the variation of the anti-inflammatory 
activity was dependent on the position and the steric hindrance of the substituent, an observation that con-
firms the link between the anti-inflammatory effect with enzyme inhibition potency and the Nrf2 induction 
properties. Regarding the substituents, in the case of the methoxy derivatives the ortho-derivative 5b showed a 
poor anti-inflammatory effect, correlating with moderate enzyme inhibition (IC50 = 16.4 μ M) and a poor Nrf2 
induction (CD > 30 μ M). When the methoxy substituent was moved to para-position (5d), anti-inflammatory 
potency was slightly increased, an improvement that correlates with an inhibitory activity 2.5-fold more potent 
(IC50 = 6.60 μ M) and a slightly improved Nrf2 induction effect (CD = 25.3 μ M). This observation was more evi-
dent in the case of the m-OMe derivative, which was 2.3 times better as a GSK3β inhibitor (IC50 = 7.20 μ M) 
Compound R IC50 nitrite reduction (μM) IC50 ROS reduction (μM)
Sulforaphane — 1.4 ± 0.3 2.84 ± 0.55
5a Ph > 60 > 60
5b 2-OCH3Ph 43.6 ± 6.45 > 60
5c 3-OCH3Ph 12.9 ± 0.86 18.1 ± 5.36
5d 4-OCH3Ph 35.4 ± 2.57 19.9 ± 4.89
5e 2-CH3Ph 34.3 ± 3.84 60.0 ± 0.29
5f 3-CH3Ph 13.4 ± 1.44 32.6 ± 6.79
5g 4-CH3Ph 22.3 ± 3.82 45.1 ± 5.33
5h 4-FPh 11.3 ± 1.15 37.0 ± 4.32
5i 2-ClPh > 60 > 60
5j 3-ClPh 5.11 ± 0.65 24.0 ± 2.58
5k 4-ClPh 26.0 ± 2.74 > 60
5l 2-BrPh 26.7 ± 1.95 38.6 ± 7.16
5m 4-BrPh 11.4 ± 2.27 33.2 ± 7.36
5n 2-NO2Ph 15.8 ± 5.23 19.9 ± 4.89
5o 3-NO2Ph 40.8 ± 2.23 30.8 ± 4.99
5p 4-NO2Ph 26.7 ± 4.86 > 60
5q 2-Furyl 17.5 ± 2.45 22.5 ± 7.78
5r 2-Thienyl > 60 > 60
5s 3-Pyridyl 7.23 ± 1.10 15.2 ± 3.73
5t 4-Pyridyl 28.8 ± 3.61 37.8 ± 1.17
Table 2.  Anti-inflammatory properties of compounds 5a–t. IC50 values of nitrite production reduction 
and ROS production reduction elicited by compounds 5a–t in primary glial cultures treated with LPS (1 μ g/
mL) during 18 h (nitrite production) and 3 h (NOX activity derived ROS production). Primary glial cultures 
were treated with increasing concentrations of the corresponding compound for 24 h. Then, treatments were 
removed and glial cells were co-incubated with the corresponding compound at increasing concentrations and 
LPS (1 μ g/mL) for 18 h. ROS production was measured after 24 h pre-incubation with increasing concentrations 
of the corresponding compound followed by 18 h of co-incubation with LPS and 3 h with the fluorescent dye. 
Data are expressed as the concentration required to inhibit 50% the liberation of nitrites induced by LPS (IC50). 
Data are means ± SEM of four different experiments in duplicate.
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compared to the ortho-derivative, and also a better Nrf2 inducer (CD = 11.3 μ M). This behavior was repeated for 
electron-withdrawing substituents, such as chlorine and bromine substituents.
The nitro derivatives 5n (o-NO2), 5o (m-NO2) and 5p (p-NO2) deserve a special mention since they fol-
lowed an opposite tendency, as described above for the GSK3β inhibition and Nrf2 induction properties. For 
this substituent, the poorest anti-inflammatory activity was found for compound 5o, bearing an m-nitro sub-
stituent. This result correlates with a moderate inhibitory activity (IC50 = 7.20 μ M) and medium Nrf2 induction 
properties. Finally, while most ortho-substituted derivatives demonstrated to be poor anti-inflammatory agents, 
the o-nitro substituted derivative showed good anti-inflammatory effect. Compound 5n (o-NO2) showed the 
best GSK3β inhibitory activity (IC50 = 3.89 μ M) and a potent Nrf2 induction capability, being the most active of 
the three -NO2 analogues in both biological activities. This observation further confirms the dependence of the 
anti-inflammatory effect on both targets.
Besides the increase in nitrite production, it is well known that LPS stimulation of microglia also induces the 
activation of NOX, which induces superoxide free radical production56. In fact, this mechanism is synergistic with 
the expression of iNOS and the production of nitrites. In this respect, there is a body of evidence showing that 
NOX activation is a major contributor to ROS oxidative stress and neuronal death in AD57,58. Thus, we deemed it 
of interest to demonstrate whether compounds 5a–t were also able to reduce ROS production upon stimulation 
with LPS. As shown in Table 2, most of the compounds successfully reduced ROS production measured by using 
the ROS sensitive dye H2DFCDA (see Supporting Information). In this case the reduction of ROS production 
afforded by the compounds showed a similar trend to that observed in the nitrite production assay; however, the 
IC50s were higher for this assay when compared to the nitrite values. In general, potency to reduce ROS production 
increased from ortho to para and meta as observed above. Similarly, nitro derivatives 5n (o-NO2), 5o (m-NO2) 
and 5p (p-NO2) showed an inversion of the general tendency being compound 5o (m-NO2, IC50 = 30.8 μ M) 
less potent than the corresponding ortho-derivative 5n (IC50 = 19.9 μ M). These results further confirm the rela-
tionships observed in the case of nitrite reduction on the dependency of both mechanism of action exerted by 
compounds 5a–t.
Compound 5c reduced TNFα production, NOX activity, NOX2 and iNOS expression induced 
by LPS and induced HO-1 expression in glial cultures. To further demonstrate the anti-inflammatory 
capacity of these compounds, we measured the most important mechanism of ROS production related to neu-
roinflammation (NOX activity, NOX2 and iNOS expression) and the TNFα release induced by LPS as markers 
of glial activation. TNFα is considered one of the most important pro-inflammatory cytokines. For this study, we 
selected compound 5c (Ar = m-OMeC6H4) that showed good properties as a GSK3β inhibitor and Nrf2 inducer, 
and the best neuroprotective profile in both neuroprotection models. Furthermore, 5c significantly reduced 
nitrite production in a concentration dependent manner (Fig. 6A). Interestingly, as shown in Fig. 6, compound 
5c was able to block the production of TNFα (Fig. 6B) in a concentration-dependent manner and to reduce the 
expression of the iNOS enzyme at 30 μ M (Fig. 6C) almost completely. The production of TNFα induced by LPS 
was reduced by 33% at 10 μ M and by 50% at 30 μ M. Interestingly, we also demonstrated that compound 5c was 
able to increase the expression of HO-1 2.3 times in glial cultures (Fig. 6D). As described above, LPS stimulation 
induces the activation of NOX enzyme to produce high amounts of superoxide; compound 5c was able to signif-
icantly reduce the activity of NOX (p < 0.01) in a concentration dependent manner from 10 to 60 μ M (Fig. 6E) 
measured after 4 h stimulation with LPS (1 μ g/mL). To further confirm the anti-inflammatory potential of com-
pound 5c we measured the expression of thre NOX2 enzyme, since this isoform has been widely described as 
being specific tomicroglial cells59,60. As depicted in Fig. 6F, LPS (1 μ g/mL) stimulation of primary glial cultures 
during 24 h increased the expression of NOX2 by 65.3% (p < 0.01) compared to basal conditions. Finally, com-
pound 5c (30 μ M) abolished almost completely (11.1% increase; p < 0.001) the over-expression of NOX2 induced 
by LPS (p < 0.01).
Toxicological evaluation. In general, Nrf2 inducers are electrophilic compounds, which tend to be hepato-
toxic, limiting their therapeutic use. Furthermore, hepatotoxicity is one of the major reasons for drug withdrawals 
in clinic61–65. Thus, it is relevant to study the potential neurotoxicity and hepatotoxicity of the novel dual GSK3β 
inhibitors-Nrf2 inducers 5a–t. As shown in Table 3 of the Supporting Information, none of the described com-
pounds revealed a significant toxicity in any of the cell lines used, namely the SH-SY5Y neuroblastoma cell line 
and the HepG2 hepatoblastoma cell line. In both cell lines, all compounds demonstrated low toxicity, with LD50 
values over 100 μ M, showing a good safety profile. Compared to the potent Nrf2 inducer sulforaphane (SH-SY5Y, 
LD50 = 13.3 μ M; HepG2, LD50 = 9.9 μ M), all these derivatives were, at least, 10 times less toxic.
Conclusions
In summary, we report here the first examples of compounds with dual activity as GSK3β inhibitors - Nrf2 induc-
ers as a multitarget approach for the treatment of AD. This combination of activities represents an interesting and 
novel approach against AD. Our data show that the Nrf2 induction capability of these compounds is an intrinsic 
pharmacological property of the 2,4-dihydropyrano[2,3-c]pyrazole core and is independent of GSK3β inhibition, 
as demonstrated by: (1) a representative example of its dihydropyridine-fused isosteric framework (compound 
7) was completely unable to induce Nrf2; (2) pharmacological ablation of GSK3β activity did not abolish Nrf2 
induction capacity of compound 5m; and (3) knockdown of GSK3β with siRNA did not affected this capacity 
either. Further studies to demonstrate the mechanism of action by which these compounds are able to induce the 
activation of the phase II antioxidant response are under development in our laboratory and will be reported in 
due course. Furthermore, the combination of activities achieved led to interesting structure-activity relationships 
linking both properties with their neuroprotective and anti-inflammatory capabilities. These relationships will 
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enable us to undertake a future hit-to-lead optimization process to obtain a lead molecule with an improved 
pharmacological profile.
In conclusion, the combination of GSK3β inhibition and Nrf2 induction in one molecule, described here for 
the first time, is aimed at decreasing tau hyperphosphorylation, to reduce oxidative stress and to diminish chronic 
neuroinflammation, that are major pathological hallmarks of AD.
Methods
Chemistry. All reagents (Aldrich, Fluka, SDS, Probus) and solvents (SDS) were of commercial quality and 
were used as received. Reactions were monitored by thin layer chromatography using commercially available 
aluminum-backed plates coated with silica gel Scharlau Cf 530 with fluorescent indicator and visualized under 
ultraviolet light lamp Camag UV-II (at 254 and 366 nm). Flash column chromatography was carried out using 
Figure 6. Nitrites (A), TNFα (B), iNOS (C) and NOX activity (E) blockade (D) and NOX2 production (F) 
by 5c in primary glial cultures stimulated with LPS (1 μ g/mL), HO-1 expression induced by this compound 
after 24 h. Primary glial cells cultures were treated with compound 5c at increasing concentrations (3, 10, 30 
and 60 μ M) for 24 h, thereafter, treatments were removed and glial cells were co-incubated with compound 5c 
at increasing concentrations and LPS (1 μ g/mL) for 18 h more. To measure NOX2 and HO-1 expression glial 
cultures were treated with compound 5c (30 μ M) for 24 h. NOX activity was measured after 4 h co-treatment 
with LPS and compound 5c. Data are means ± SEM of four different experiments in triplicate. ###p < 0.001 
compared to basal levels; ***p < 0.001; **p < 0.01; *p < 0.05 compared to LPS condition.
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silica gel SDS 60 ACC or Scharlau Ge 048 and the eluent indicated in each case. Automatic flash chromatogra-
phy was performed in a Teledyne ISCO COMBI Flash Rf instrument using RediSep Rf silica columns (4 g and 
12 g) or self packed silica cartridges. Melting points were determined using a Stuart Scientific apparatus, SMP3 
Model, and are uncorrected. All compounds were characterized using spectroscopic data and HRMS. The purity 
of new compounds was assessed by CHNS elemental analysis, and all values were verified to be within ± 0.4% 
of the theoretical values. Infrared spectra were recorded on an Agilent Cary630 FTIR spectrometer with a dia-
mond ATR accessory for solid and liquid samples, requiring no sample preparation. NMR spectra were obtained 
on a Bruker Avance 250 spectrometer operating at 250 MHz for 1H and 63 MHz for 13C (CAI de Resonancia 
Magnética Nuclear, Universidad Complutense). Gas chromatography mass spectra (GC-MS) were taken with 
different ionization methods, as Electronic Impact (EI) or Electrospray Ionization (ESI) in both the positive 
and negative ion mode, and were carried out by SIDI from Universidad Autónoma de Madrid (Madrid, Spain). 
Quantitative elemental analysis by combustion of carbon, hydrogen, nitrogen and sulfur were carried out in 
Servicio de Microanálisis Elemental from Universidad Complutense (Madrid, Spain), using a Leco CHNS 932 
Elemental Analyzer.
General procedure for the synthesis of 2,4-dihydropyrano[2,3-c]pyrazole derivatives 5a–t. A 
solution of pyrazolone derivative 3 (1 equiv, 1 mmol), malononitrile (1 equiv, 1 mmol), the corresponding 
arylaldehyde 4a–t (1 equiv, 1 mmol) and ammonium acetate (1 equiv, 1 mmol) in ethanol (2 mL) was heated 
under reflux for 5 hours. After this time the solvent was evaporated under reduced pressure and the crude resi-
dues were crystallized from EtOH or purified by silica gel column chromatography using dichloromethane:meth-
anol mixtures as eluent to give pure compounds (5a–t). For characterization data for all final compounds; see the 
Supporting Information.
Pharmacology
GSK3β inhibition. GSK3β inhibitory activity was evaluated using the method developed by Baki66, with 
modifications. Compounds were dissolved in assay buffer, containing 40 mM Tris (pH 7.5), 20 mM MgCl2, 
0.1 mg/ml BSA (bovine serum albumin) and 50 μ M dithiothreitol (DTT) at the desired concentrations. Firstly, 
10 μ l of enzyme (10 ng) and 10 μ l of each compound were mixed for 30 min. Then, 20 μ l of a mixture of ATP 
(1 μ M) and GSK3β peptidic substrate were added to each well. The mixture was incubated for 60 min at 30 °C. 
Thereafter, the remaining ATP concentration was measured with the Kinase-Glo system following instructions 
from the supplier. Luminescence was measured in an Orion II microplate luminometer (Berthold, Germany) as 
relative light units (RLU). GSK3β activity is proportional to the difference between total ATP and remaining ATP 
after the enzymatic reaction, activity was considered to be 100% in the absence of an inhibitor. IC50 values were 
calculated by non-linear regression analysis of individual concentration-response curves using GraphPad Prism 
5.0 software (San Diego, CA, USA).
Luciferase activity: Nrf2 induction. AREc32 cells were plated in 96-well white plates (2 × 104 cells/well). 
After 24 h, cells were incubated with increasing concentrations of each compound in duplicate for 24 h. AREc32 
cells express constitutively the plasmid pGL-8xARE that implements 8 copies of the EpRE sequences followed 
by luciferase reporter gen. Therefore, Nrf2 induction is related to the activation of EpRE sequences, expressing 
luciferase at the same extent as EpRE sequences are activated. The Luciferase Assay System (Promega E1500), was 
used according to provider protocol and luminescence was quantified in an Orion II microplate luminometer 
(Berthold, Germany). Fold induction of luciferase activity was normalized to basal conditions. Data are expressed 
as CD values, expressing the concentration required to double the luciferase activity. CD values are calculated 
from dose-response curves generated from fold induction of control conditions vs. inducer concentration and 
fitted by non-linear regression and data interpolated to 2-fold induction concentration.
Docking calculations. The GSK3β crystallographic structure PDB ID 1PYX containing phosphoamino-
phosphonic acid-adenylate ester (AMP-PNP), was used to perform the molecular docking. To test our system, we 
first performed the docking of ANP at the ATP-binding site using AutoDock Vina (version 1.1.2). Calculations 
were run on a PC with a 2.1 GHz-i3 processor and 4 GB RAM. The results were visualized employing PyMOL 
(version 1.8, Schrödinger). The docking result for the crystallised ligand was overlayed with the co-crystal 
structure and the calculated exhaustive root mean squared deviation (RMSD) was 0.908, indicating a good pre-
diction ability of our docking protocol. We decided to carry out a rigid molecular docking due to close simi-
larity in the binding site between different crystallographic structures from different inhibitors. The selected 
2,4-dihydropyrano[2,3-c]pyrazole heterocyclic scaffold could be successfully docked using the validated docking 
protocol for GSK3β . Positions were also inspected and compared with the score algorithm, protein interaction, 
hydrogen bonding, and affinity interaction energies and ordered by the energy of interaction protein-ligand. 
Complexes were optimized using Moloc software67 (www.moloc.ch) with standard force field and optimization 
parameters. During energy minimization the position of amino acid side chains were fixed while allowing all 
ligand atoms to move.
siRNA assay. The short interfering RNA (siRNA) used to knock down human GSK3β expression and the 
control scrambled siRNA sequence were purchased from Thermo Fisher Scientific siRNA identifier ID s6241 for 
GSK3β . Briefly, AREc2 cells were seeded in 6-well plates (300,000 cells/well in 2 ml complete medium without 
antibiotics). We knocked down GSK3β using 25 nM of the siRNA with 2 μ l DharmaFECT1 transfection reagent 
(GE Dharmacon, T-2001-01). 48 h later, the cells were collected and GSK-3β levels were analyzed. Another set 
of cells were treated with scramble or siRNA for GSK3β as described for 48 h and thereafter AREc32 cells were 
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treated with control media (basal conditions) or compound 5c 10 μ M for 24 h more. Then cells were collected to 
analyze luciferase activity, HO-1 and GSK3β expression.
Neuroprotection in the SH-SY5Y neuroblastoma cell line. A pre- and co-incubation protocol was 
followed. Cells were pre-incubated with the corresponding compound at 1 μ M in neuroblastoma cells culture 
medium. After 24 h, medium was removed and replaced with 1% FBS neuroblastoma culture media containing 
the corresponding compound (1 μ M) and the toxic stimuli, the mixture of rotenone and oligomycin A (30 μ 
M/10 μ M respectively) or okadaic acid at 20 nM. Cells were co-incubated for further 24 h with the rotenone and 
oligomycin A solution or 18 h with the okadaic acid solution. Control cells were incubated with the same amount 
of DMSO without any drug. After the co-incubation period, cell viability was assessed by the MTT-reduction 
method.
Nitrite production measurement in culture medium of mixed glial cells. Glial cells were 
pre-incubated with increasing concentrations of compounds for 24 hours. Then, treatments were removed and 
cells were incubated with LPS (1 μ g/mL) alone or in presence of each compound at the desired concentration. 
Nitrite production was assessed 18 hours later by modified Griess assay. Briefly, samples (150 μ l) were mixed with 
dapsone (75 μ l) and NEDA (75 μ l), and the mixture was incubated at room temperature for 5 min. Light absorp-
tion was measured at 550 nm in a microplate reader (Labtech, Offenburg, Germany). All data were normalized 
to basal nitrite production, considering this value as 100% of nitrite production. IC50 values were calculated from 
dose-response curves represented as percentage of nitrite production reduction induced by the different concen-
trations of each compound.
ROS production measurement. Primary glial cells were cultured in bottom transparent 96-well black 
plates following standard protocol. Cells were pre-incubated with the corresponding compound at the selected 
concentrations, for 24 hours, and therafter, co-incubated with the corresponding compound and LPS (1 μ M) 
during 18 h more. Then, treatments were removed and cells were loaded with the fluorescent probe 2′ ,7′ 
-dichlorodihydrofluorescein diacetate (H2DCFDA) (10 μ M) for 45 minutes in serum free glial culture medium. 
All experiments included cells treated with culture medium alone (basal). Cells were washed twice with culture 
medium and fluorescence intensity was recorded in a Fluostar Optima multiwall pate reader (BMG Labtech, 
Offenburg, Germany) at 485/520 nm as excitation and emission wavelengths respectively, each hour, during 
3 hours period. Data were normalized with respect to basal conditions that were considered as 100%.
Quantification of TNFα levels in the culture medium of mixed glial cells. Tumor necrosis 
factor-alpha (TNFα ) concentrations were measured by specific quantitative sandwich ELISA kits (Preprotech, 
R&D Systems-bioNova, Madrid, Spain) following manufacturer instructions. TNFα levels in supernatant sam-
ples, obtained after treatments with culture media (Basal), LPS or LPS co-incubated with increasing concentra-
tions of compound 5c, were measured following manufacturer instructions. A standard curve was generated 
using the OD values of standard solution of TNFα . Light absorption was measured in a microplate reader 
(Labtech, Offenburg, Germany).
Western Blot. After treatment, mixed glial cells were washed with cold PBS and lysed in 100 μ l ice-cold lysis 
buffer (1% Nonident P-40, 10% glycerol, 137 mM NaCl, 20 mM Tris HCl pH 7.5, 1 μ g/ml leupeptin, 1 mM phen-
ylmethylsulfonyl fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, and 1 mM Na3VO4). Then, proteins (30 μ 
g) from cell lysates were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred 
to Immobilon-P membranes (Millipore Ibérica SA, Madrid, Spain). Membranes were incubated with anti-iNOS 
(BD Transduction Laboratories, USA) at 1:1000, anti-HO-1 (Chemicon, Hampshire, UK) at 1:1000, anti-GCLc 
(Chemicon, Hampshire, UK) at 1:1000, anti-gp91-phox (NOX2, sc-130543, Santa Cruz, Madrid, Spain) at 1:500, 
Anti-GSK3β (610201, BD Transduction Laboratory) at 1:2000 and anti-β -actin at 1:100,000 (Sigma, Madrid, 
Spain). Peroxidase-conjugated secondary antibodies (1:10000) were used to detect proteins by enhanced chemi-
luminescence detected by Advance Western-blotting Detection Kit (GE Healthcare, Barcelona, Spain). Scion 
Image program was used to quantify band intensities corresponding to immunoblot detection of protein samples. 
Immunoblots correspond to a representative experiment that was repeated 4 times with similar results.
NOX activity assay. Cells were pre-incubated with increasing concentrations of the compound. After 
24 hours, treatments were removed and cells were incubated with LPS (1 μ g/mL) in presence of the compound at 
increasing concentrations for additional 4 h. Then, treatments were removed and NADPH oxidase activity was 
assessed by measuring O2− production in the presence of the substrate, NADPH (100 μ M) as lucigenin-enhanced 
chemiluminiscence (5 μ M lucigenin). No enzymatic activity was detected in the absence of NADPH. 
Luminescence was recorded 29 times every 1.8 seconds for each well in a luminometer, and NADPH oxidase 
activity was expressed as relative light units (RLU)/min normalized to basal value.
Statistical analysis. All values are expressed as mean ± S.E.M. IC50 and LD50 values were calculated by 
non-linear regression analysis of individual concentration-response curves using GraphPad Prism (version 5) 
software (San Diego, CA, USA). Analysis of the results was performed by comparison of experimental and control 
data by One-way or two-way ANOVA followed by Newman-Keuls post-hoc test. Differences were considered to 
be statistically significant when p ≤ 0.05. “n” represents the number of different cultures used or enzyme inhibi-
tion assays performed.
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